|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
41,560,000 |
Market
Cap: |
275.54(M) |
Last
Volume: |
5,200 |
Avg
Vol: |
5,185 |
52
Week Range: |
$3.61 - $10.69 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
118,082 |
130,582 |
180,030 |
368,410 |
Total Sell Value |
$980,899 |
$1,074,708 |
$1,509,387 |
$3,484,755 |
Total People Sold |
5 |
6 |
6 |
6 |
Total Sell Transactions |
6 |
7 |
9 |
21 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Zaderej Karen L. |
CEO |
|
2024-03-21 |
4 |
S |
$7.68 |
$301,670 |
D/D |
(39,280) |
1,143,788 |
|
15% |
|
Scopelianos Angelo |
Chief R&D Officer |
|
2024-03-21 |
4 |
S |
$7.68 |
$52,846 |
D/D |
(6,881) |
57,994 |
|
15% |
|
Scopelianos Angelo |
Chief R&D Officer |
|
2024-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
58,604 |
|
- |
|
Devinney Erick Wayne |
Chief Innovation Officer |
|
2024-03-21 |
4 |
S |
$7.68 |
$35,159 |
D/D |
(4,578) |
177,474 |
|
15% |
|
Donovan Michael Patrick |
VP Operations |
|
2024-03-21 |
4 |
S |
$7.68 |
$46,333 |
D/D |
(6,033) |
54,250 |
|
15% |
|
Zaderej Karen L. |
CEO |
|
2024-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
110,322 |
1,146,954 |
|
- |
|
Scopelianos Angelo |
Chief R&D Officer |
|
2024-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,406 |
57,124 |
|
- |
|
Devinney Erick Wayne |
Chief Innovation Officer |
|
2024-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,675 |
180,615 |
|
- |
|
Donovan Michael Patrick |
VP Operations |
|
2024-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,575 |
58,846 |
|
- |
|
Freitag Gregory Gene |
Director |
|
2024-03-07 |
4 |
S |
$9.00 |
$225,000 |
D/D |
(25,000) |
271,594 |
|
28% |
|
Donovan Michael Patrick |
VP Operations |
|
2024-03-07 |
4 |
S |
$8.81 |
$319,891 |
D/D |
(36,310) |
35,708 |
|
28% |
|
Devinney Erick Wayne |
Chief Innovation Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
163,377 |
|
- |
|
Kemp Jens |
Chief Marketing OfficerOfficer |
|
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000 |
|
-6% |
|
Naor Nir |
CFO |
|
2024-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
Mariani Peter J |
EVP & Chief Financial Officer |
|
2023-12-11 |
4 |
S |
$7.50 |
$93,809 |
D/D |
(12,500) |
63,603 |
|
8% |
|
Mariani Peter J |
EVP & Chief Financial Officer |
|
2023-10-13 |
4 |
D |
$4.04 |
$13,183 |
D/D |
(3,263) |
76,103 |
|
- |
|
Devinney Erick Wayne |
VP Peripheral Nerve Science |
|
2023-10-13 |
4 |
D |
$4.04 |
$3,491 |
D/D |
(864) |
113,377 |
|
- |
|
Martinez Maria D. |
Chief Human Resources Officer |
|
2023-10-13 |
4 |
D |
$4.04 |
$5,668 |
D/D |
(1,403) |
30,476 |
|
- |
|
Scopelianos Angelo |
Chief R&D Officer |
|
2023-10-13 |
4 |
D |
$4.04 |
$5,668 |
D/D |
(1,403) |
36,969 |
|
- |
|
Donovan Michael Patrick |
VP Operations |
|
2023-10-13 |
4 |
D |
$4.04 |
$5,668 |
D/D |
(1,403) |
72,018 |
|
- |
|
Wendell Amy Mcbride |
Director |
|
2023-09-06 |
4 |
B |
$6.22 |
$62,240 |
D/D |
10,000 |
80,342 |
2.39 |
29% |
|
Burke Willaim P |
Director |
|
2023-08-24 |
4 |
A |
$6.31 |
$37,860 |
D/D |
6,000 |
6,000 |
|
- |
|
Burke Willaim P |
Director |
|
2023-08-23 |
4 |
B |
$6.56 |
$65,600 |
I/I |
10,000 |
10,000 |
2.1 |
6% |
|
Neels Guido J |
Director |
|
2023-08-16 |
4 |
B |
$6.11 |
$61,100 |
D/D |
10,000 |
68,259 |
2.39 |
24% |
|
Mariani Peter J |
EVP & Chief Financial Officer |
|
2023-07-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,709 |
79,366 |
|
- |
|
529 Records found
|
|
Page 1 of 22 |
|
|